Persistent CAR-T cells in the intestine and widespread immune disruption seen as possible drivers of a rare but serious complication Researchers at the Icahn School of Medicine at Mount Sinai have identified biological mechanisms that may contribute to CAR-T cell-associated enterocolitis, a serious inflammatory condition of the intestine that can occur after a type of
PANXEON, which combines multiple biomarkers, also identified a precancerous condition of the pancreas, potentially opening a path to intervention before invasive cancer develops One reason pancreatic cancer remains so deadly is because it’s usually discovered late, after it has spread. Now, a major new study shows that a blood test developed by researchers led by
First and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for these patients in the adjuvant melanoma setting The Companies plan to present data at an upcoming international medical meeting and will engage with regulators on filing submissions for intismeran autogene in combination with
At the ASCO annual meeting, Dana-Farber’s Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy. A shift in the way people
Gene edits could solve obstacles to treatment for the most common types of cancer Since 2017, a personalized immunotherapy called Chimeric Antigen Receptor, or CAR-T cell treatment, has worked wonders to treat patients with blood cancers such as leukemia. But when it comes to treating solid tumor cancers, such as lung, breast and kidney cancers
Results of a phase 1 clinical trial show that patients who undergo a blood stem cell transplant involving a donor have a lower risk of relapse and lower rates of graft-versus-host disease when they receive the targeted therapy VIC-1911 along with the standard-of-care regimen that includes post-transplant cyclophosphamide and sirolimus. Led by Shernan Holtan, MD, Chief of Blood
Chinese researchers have developed a novel method to efficiently engineer natural killer (NK) cells for cancer immunotherapy. NK cells are central to early antiviral and anticancer defense—among other immune system roles—making them well-suited for cancer immunotherapy. For example, chimeric antigen receptor (CAR)-NK therapy involves adding a lab-built receptor (a CAR) to an NK cell, enabling
Adding a personalised mRNA vaccine to plain remedy might supply new hope for pancreatic cancer sufferers, a small but promising study from Memorial Sloan Kettering Cancer Center. The study adopted 16 sufferers, together with Barbara Brigham, who joined the trial after a routine scan found her early-stage pancreatic cancer. Alongside surgical procedure and chemotherapy, sufferers
A bone marrow transplant process co-developed by investigators at the Johns Hopkins Kimmel Cancer Center is safe and curative for adults with sickle cell disease, according to results of a trial completed at Johns Hopkins and about 20 additional cancer centers nationwide and in London. The treatment, available at multiple U.S. medical centers, is a viable and
Called PAC-MANN, the test developed at OHSU could help save lives A new blood test could help doctors detect pancreatic cancer earlier, potentially improving survival rates for one of the deadliest cancers. Researchers at Oregon Health & Science University have developed a test called PAC-MANN, the abbreviation for “protease activity-based assay using a magnetic nanosensor,”
